You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Fig. 5

High expression of IC molecules in TILs. a A comparison of the expression levels of IC molecules in peripheral blood and tumor tissue (total of 59 samples from 18 patients). IC molecules (PD-1, CTLA-4, LAG-3, and ICOS) were highly expressed in TILs compared with PBMCs. All of them were higher in CD45RAFOXP3highCD4+ T cells (eTreg cells) than in CD8+ T cells (PD-1+CD8+ T cells and PD-1+ eTreg cells in PBMCs and in TILs [8.12% ± 5.75% vs. 12.5% ± 6.17% vs. 44.18% ± 20.7% vs. 64.01% ± 28.02%, respectively, P < 0.01 across all categories]; CTLA-4+CD8+ T cells and CTLA-4+ eTreg cells in PBMCs and in TILs [0.52% ± 0.45% vs. 20.0% ± 14.35% vs. 5.01% ± 4.35% vs. 57.96% ± 20.54%, respectively, P < 0.01 across all categories]; LAG-3+CD8+ T cells and LAG-3+ eTreg cells in PBMCs and in TILs [0.79% ± 0.78% vs. 4.05% ± 2.54% vs. 13.14% ± 6.31% vs. 18.33% ± 12.61%, respectively, P < 0.01 across all categories]; ICOS+CD8+ T cells and ICOS+ eTreg cells in PBMCs and in TILs [0.54% ± 0.51% vs. 12.94% ± 7.15% vs. 3.47% ± 2.89% vs. 50.31% ± 19.09%, respectively, P < 0.01 across all categories]). b Correlation of the expression of IC molecules in PBMCs and TILs (total of 59 samples from 18 patients). No correlation was observed between PBMCs and TILs with regard to the expression of IC molecules by CD8+ T cells or eTreg cells (PD-1, CTLA-4, LAG-3, and ICOS in CD8+ T cells, r = 0.23, 0.14, 0.13, and − 0.13, P = 0.086, 0.29, 0.34, and 0.35, respectively; in eTreg cells, r = 0.22, 0.26, 0.21, and 0.062, P = 0.094, 0.054, 0.11, and 0.65, respectively)

Back to article page